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Abstract
Background: Glioblastoma multiforme (GBM) is the most common primary intracranial tumor
and despite recent advances in treatment regimens, prognosis for affected patients remains poor.
Active cell migration and invasion of GBM cells ultimately lead to ubiquitous tumor recurrence and
patient death.
To further understand the genetic mechanisms underlying the ability of glioma cells to migrate, we
compared the matched transcriptional profiles of migratory and stationary populations of human
glioma cells. Using a monolayer radial migration assay, motile and stationary cell populations from
seven human long term glioma cell lines and three primary GBM cultures were isolated and
prepared for expression analysis.
Results: Gene expression signatures of stationary and migratory populations across all cell lines
were identified using a pattern recognition approach that integrates a priori knowledge with
expression data. Principal component analysis (PCA) revealed two discriminating patterns between
migrating and stationary glioma cells: i) global down-regulation and ii) global up-regulation profiles
that were used in a proband-based rule function implemented in GABRIEL to find subsets of genes
having similar expression patterns. Genes with up-regulation pattern in migrating glioma cells were
found to be overexpressed in 75% of human GBM biopsy specimens compared to normal brain. A
22 gene signature capable of classifying glioma cultures based on their migration rate was
developed. Fidelity of this discovery algorithm was assessed by validation of the invasion candidate
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gene, connective tissue growth factor (CTGF). siRNA mediated knockdown yielded reduced in vitro
migration and ex vivo invasion; immunohistochemistry on glioma invasion tissue microarray
confirmed up-regulation of CTGF in invasive glioma cells.
Conclusion: Gene expression profiling of migratory glioma cells induced to disperse in vitro affords
discovery of genomic signatures; selected candidates were validated clinically at the transcriptional
and translational levels as well as through functional assays thereby underscoring the fidelity of the
discovery algorithm.
Background
Glioblastoma multiforme (GBM) is the most common
primary brain tumor, affecting 20,000 patients per year;
the peak age of occurrence is between 50–60 years of age.
Despite advances in diagnosis and treatment, life expect-
ancy for patients suffering from this disease still remains
at 18 months [1]. Both genetic heterogeneity and highly
invasive behavior are believed to be responsible for recur-
rent tumor growth, which occurs typically within 3 cm of
the initial resection cavity; these behaviors also contribute
to poor therapeutic response [1]. Although invasive cells
are recognized as drivers of poor outcome, as they are left
behind after surgical debulking [2], no specific treatment
has been developed targeting this important tumor cell
subpopulation [3-5]. We have recently reported that inva-
sive GBM cells comprise a unique population that is char-
acterized by heightened resistance to induction of
apoptosis [6]. While global expression profiles of glial
tumors have been studied extensively, less is known about
gene expression in invasive glioma [7,8]. To shed light on
the biological processes that drive invasive behavior and
to identify novel candidates that may serve as targets for
specific anti-invasive therapies, we sought to develop a
discovery approach that can be applied to an in vitro
model system of glioma migration. Gene expression pro-
files of a panel of seven established glioma cell lines and
three primary glioma cultures, induced to migrate for 24
hours, were established. They revealed two signatures of
migrating and stationary glioma cells and selected candi-
dates were validated clinically on a comprehensive glioma
expression data set, a glioma invasion tissue microarray
(TMA) and functionally in migration assays and ex vivo rat
brain slice assays.
Methods
Glioma cell tissue culture
Ten GBM cell lines were selected for this study: seven
established (U87MG, T98G (ATCC), U87ΔEGFR [9]
G120, G112MS, SF763 and SF767 [10], and three primary
cultures (GH3, 4, and 6) that were kindly provided by R.
Goldbrunner, Dept. of Neurosurgery, Munich. Germany.
All tissue culture was done using 10% FBS MEM and cells
were kept at 37°C, 5% CO2 and 100% humidity. Primary
cultures were used at or under passage 5, maintained in
20% FBS MEM and switched to 10% FBS MEM twenty-
four hours prior to use in migration assay. All cell cultures
were tested for, and found to be free of, Mycoplasma sp.
infection by DAPI staining regularly.
Radial Migration Assay
The radial migration assay was performed as described
previously [11,12]. To simulate a GBM migratory front
(rim) and proliferating core, three thousand glioma cells
were seeded as a defined, confluent circular monolayer
using cell sedimentation manifolds (CSM, Inc., Phoenix,
AZ) on glioma-derived extra-cellular matrix coated 10-
well slides. Migration was initiated by removing the man-
ifold 4 hours after seeding and cells then radially dis-
persed for 24 hours. Migration rates were estimated from
photomicrographs of migration assays taken at time point
0 hours and time point 24 hours [13].
For microarray experiments, stationary (core) and migra-
tory (rim), cells were harvested under an inverse micro-
scope (Axiovert 100, Zeiss, NY) using P2 pipette in three
independent biological replicates. Thirty individual dis-
persion assays (three 10-well slides) were collected per
cell line and all materials were stored at -20°C until RNA
isolation. Core and rim cells were separately lysed with
Trizol (Invitrogen, Carlsbad, CA).
RNA isolation, amplification and labeling
Total RNA was extracted from Trizol solution, according
to manufacturer's instructions and followed with purifica-
tion through RNeasy mini kit (Qiagen, Valencia, Ca).
Total RNA quality and quantity were assessed by Bioana-
lyzer RNA 6000 Nano LabChip Kit (Agilent Technologies,
Palo Alto, CA). Samples selected for the study contained
intact RNA as determined by visual inspection of electro-
pherograms for distinct 18S and 28S ribosomal peaks.
Samples that failed this assessment were not included in
the study.
Sample (either rim or core) and human universal refer-
ence RNA (Stratagene, La Jolla, CA) underwent one round
of linear amplification and fluorescent labeling in Agi-
lent's Low-Input Linear Amplification and Labeling Kits
yielding fluorescent cRNA. Sample RNA was labeled with
Cyanine 5 (Cy5) while reference RNA was labeled with
Cyanine 3(Cy3) – CTP (PerkinElmer, Boston, MA) andBMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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cRNA concentration was assessed spectro-photometrically
(GeneQuant II, Bottom Ltd., Cambridge, UK). One hun-
dred nanograms of total RNA from each sample were
labeled for hybridization to microarray chips and remain-
ing unamplified sample RNA was saved for validation
studies. Reference RNA was amplified/labeled in replicate
reactions and pooled.
Microarray processing and quality testing
Each Cy5-labeled core and rim sample (three biological
replicates) was hybridized against Cy3-labeled universal
reference RNA on whole human genome 40 K oligonucle-
otide microarray chips (Agilent) according to manufac-
ture's protocol [14]. Agilent DNA microarray scanner and
Feature Extraction Software with default settings for oligo-
nucleotide expression arrays were used to capture and
process array images. Spot intensities were extracted and
preprocessed by subtracting background noise and apply-
ing a LOWESS (locally weighted linear regression) correc-
tion for dye-bias [14]. Preprocessed data was then filtered
by removing genes with a background signal higher than
feature signal. Log2 (S/R) (S = sample (rim or core) and R
= universal reference) for each gene was calculated.
Technical variation (i.e. variation due to instrumentation,
assays and reagents) was assessed with two sets of techni-
cal triplicates. One collected at the beginning of the study
and one at the end. A comparison of variation in technical
and biological triplicates from the same cell line (T98G)
was done to determine if technical variation was the same
or greater than biological variation. Variation was qualita-
tively assessed by overlaying standard deviation versus
average gene expression for each set of technical triplicates
with their corresponding biological replicates. Expression
values were log2 ratio of ratios, which is calculated by
dividing rim ratio (rim/universal reference) by core ratio
(core/universal reference).
Data analysis
A minimum fold change threshold was established by cal-
culating the median standard deviation of rim/core
expression for each biological replicate (n = 3). Genes that
were not statistically (p > 0.1) differentially expressed
were identified with ANOVA and removed. Genes that are
not differentially expressed are considered non-informa-
tive and removed to reduce the complexity of the data.
In order to identify genes whose expression was consist-
ently up- or down-regulated in rim cells as compared to
their corresponding core cells across all cell lines, a pattern
recognition approach integrating a priori knowledge about
transcriptional differences between rim and core popula-
tions was employed. Principal component analysis (PCA)
was used to determine components of variation in the
data whereby patterns can be identified that discriminate
samples (i.e. rim from core) [15,16]. Genes whose profiles
correlate (r > 0.6 and are visually similar) with the dis-
criminatory PCA-derived patterns serve as probands and
are used in the proband-based rule function within the
Genetic Analysis By Rules Incorporating Expert Logic
(GABRIEL), a platform of knowledge-based algorithms
that incorporate biological knowledge to enable system-
atic microarray analysis, to find sub-sets of genes with
similar expression patterns [17]. One of GABRIEL's func-
tions can readily identify additional genes whose expres-
sion profiles correlate with those of pre-selected proband
genes. Both false discovery and false negative rates (FDR
and FNR, respectively) are used to estimate significance of
selected genes compared to random chance [18]. Proband
analysis was performed with the correlation coefficient
threshold set at 0.8 for each proband. Genes identified
were categorized according to their Gene Ontology into
classes deemed significant for glioma biology.
Migration rates from the replicates of the 7 glioma cell
lines and 3 primary cultures were averaged and binned
into fast (>average migration rate) and slow migration
(<average migration). Significance analysis of microarrays
(SAM) was carried out on the union of migratory and sta-
tionary signatures derived from GABRIEL in order to iden-
tify significantly different genes between fast and slow
migration groups. Support vector machines (SVM) with a
linear kernel using leave-1-out crossvalidation were used
to predict migration rate (e.g. fast or slow) based on gene
signatures. A permutation test (10,000 iterations) was per-
formed to assess the performance of the classification.
Clustering of the migration rate signature in the malig-
nant astrocytoma cases was performed using k-means and
visualized using multidimensional scaling (MDS) plots.
Kaplan-Meier analysis were used to assess survival differ-
ences between clusters.
TM4 [19] was used for SAM. Survival analysis was done
with SPSS (SPSS Inc., Chicago, IL). ANOVA, PCA, SVM, k-
means, and MDS was performed with MATLAB (Math-
Works, Inc. Natick, MA)
Gene expression profiling of human brain tumor specimen
Gene expression data of 111 glial tumors and 24 normal
brain specimens was kindly provided by Dr. T. Mikkelsen,
Henry Ford Hospital, Detroit MI and Dr. H. Fine Neuro
Oncology Branch, National Cancer Institute, National
Cancer Institute, Bethesda, MD. Array data was processed
according to Affymetrix® MAS5 (Microarray Suite 5) algo-
rithm implemented in Affymetrix®  GCOS (GeneChip
Operating Software). Text files exported from GCOS were
uploaded into GeneSpring®7.2 for data management (Sil-
icon Genetics, Redwood City, CA).BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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Gene symbols and accession numbers were used to map
Agilent probes to Affymetrix probes using Affymetrix's
Netaffx tool.
QRT-PCR Validation
QRT-PCR was performed with the unamplified RNA col-
lected for use in microarray experiments. One hundred
nanograms of RNA from each biological replicate were
reverse transcribed (Supersrcipt III, Invitrogen) using
oligo-dT primers. cDNA was diluted 1:4 in water and aliq-
uoted until use. Primers were designed to hybridize in the
3'prime region of the genes and to produce amplicons
ranging from 100 to 300 base pairs. Relative quantifica-
tion was performed on the LightCycler Instrument
(Roche, Mannheim, Germany) using LightCycler FastStart
DNA Master SYBR Green I and normalized to Histone 3A
as a housekeeping gene. Specificity of PCR amplicons was
confirmed by melting curve analysis [20] and agarose gel
electrophoresis.
Crossing points of target gene vs. housekeeping gene His-
tone 3A were used to calculate relative fold up-/down-reg-
ulation in the invasive cells with the following formula: F
= 2(IH-IG)-(CH-CG), adapted from [21], where F = fold differ-
ence, C = core cells, I = invasive rim cells, G = gene of inter-
est, H = housekeeping (Histone 3A).
Immunofluorescence
In vitro protein expression of CTGF was assessed by
immunofluorescence staining of migrating and stationary
T98G cells in migration format. After induction of migra-
tory phenotype for 24 hours cells were fixed with 4% para-
formaldehyde, permeabilized with 0.5% triton X-100,
blocked with 3% goat serum in tris-buffered saline (TBS)
for 30 minutes, and incubated at room temperature for
one hour with anti-CTGF antibody (SC-25440, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:100. Addi-
tion of Cy3 conjugated secondary antibody (Jackson Lab-
oratories, West Grove, PA) for one hour at room
temperature (1:2000) was completed and cells were
viewed with a LSM 5 Pascal laser scanning confocal micro-
scope (Zeiss, Thornwood, NY).
Immunohistochemistry
A glioma invasion specific TMA [7] was used for immuno-
histochemical evaluation of proteins in stationary and
invasive glioma cells. Briefly, the TMA was heated for 2
hours at 65°C, deparaffinized in xylene and hydrated in a
graded alcohol series. Endogenous peroxidases were
quenched with 3% hydrogen peroxide in PBS for 15 min-
utes, followed by antigen retrieval using reveal solution in
the Decloacking Chamber (Biocare Medical, Concord,
CA). Non-specific binding was blocked with 10% normal
goat serum in 0.1% Triton X-100 TBS for 1 hour at room
temperature. Slides were then incubated with CTGF anti-
body (1:200) at 4°C overnight, washed and secondary
antibody (Vectastain Kit; Vector Laboratories, Burlin-
game, CA) was applied at room temperature for 1 hour.
Slides were exposed to diaminobenzidine (Sigma, St.
Louis, MO) for 1 minute and counterstained with hema-
toxylin 2 (Richard-Allen Scientific, Kalamazoo, MI). TMA
was evaluated by a pathologist (S.N.) where percentage of
cells exhibiting no(0), weak(+), moderate(++) and strong
immunopositivity(+++) was assessed as described previ-
ously [7,22]; Pearson chi-square test was employed to
compare staining intensity in rim and core population.
Functional studies
Purified, duplexed siRNAs for CTGF and for luciferase
(control) were purchased from Qiagen (Valencia, CA).
The siRNA sequences targeting human CTGF (GenBank
accession number NM_001901) were GTCCCGGA-
GACAATGACATCT (C1) and ATCGGAATCCTGTCGATT-
AGACT (C2). The sequences were designed to be unique
when compared with the sequence of other CCN mem-
bers. The sequence targeting luciferase was AACG-
TACGCGGAATACTTCGATT. Glioma cells (8 × 105) were
transfected with 20 nM of siRNA using lipofectamine
2000 (Invitrogen) and cultured for 48 hours prior to use.
In-vitro migration assays were performed on 10-well slides
coated with 10 μg/ml laminin.
Ex Vivo Invasion Assay on Rat Brain Slices
An ex vivo invasion assay on rat brain slices was carried out
as described previously [13,23]. Briefly, 400 μm thick sec-
tions were prepared from Wistar rat (Crl:(WI)BR; Charles
River Lab, Wilmington, MA) cerebrum. Approximately 1 ×
105 glioma cells stably expressing green fluorescence pro-
tein (GFP) were gently placed (0.5 μl transfer volume) on
the brain slice in 4–6 replicates per condition. After 72
hours, glioma cell invasion into the rat brain slices was
quantitated using a LSM 5 Pascal Laser scanning confocal
microscope (Zeiss, Thornwood, NY). Serial optical sec-
tions were obtained every 5 μm downward from the sur-
face plane to the bottom of the slice. The invasion rate was
calculated as described previously [13]. In brief, for each
focal plane, the area of fluorescent cells was calculated
and plotted as a function of the distance from the surface
of the brain slice.
Antibodies and Immunoblotting
Glioma cells or glioma tissue specimens were lysed in
sample buffer as described previously [23] and separated
by 10% SDS-polyacrylamide gel electrophoresis, trans-
ferred to nitrocellulose membrane (Invitrogen) and
probed with specific antibodies. Horseradish peroxidase-
conjugated secondary antibodies were detected using a
chemiluminescence system (NEN, Boston, MA). Follow-
ing stripping, membranes were re-probed with α-tubulinBMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
Page 5 of 15
(page number not for citation purposes)
antibody. Bound secondary antibodies were detected
using a chemiluminescence system (NEN, Boston, MA).
CTGF antibody was from Santa Cruz Biotechnology
(Santa Cruz, Ca) and α-tubulin antibody was from
Upstate Biotechnology (Lake Placid, NY). Horseradish
peroxidase coupled secondary antibodies were purchased
from Promega (Madison, WI).
Results
In vitro glioma migration microarray data analysis
RNA was isolated from migratory and stationary glioma
cells harvested as three biological replicates from the
radial migration assay. RNA integrity was confirmed with
the Bioanalyzer by the presence of well-defined 18s and
28s ribosomal RNA bands; the median yield per biologi-
cal replicate was 700 ng. Microarray analysis of migratory
glioma cells compared to their stationary cognates was
performed using the three biological replicates derived
from seven glioma cell lines and three primary cultures.
Median standard deviation of rim/core expression for
three biological replicates was ± 1.23-fold with a 95%
confidence interval at ± 1.5-fold, leading to a detection
limit of ± 1.5-fold change between rim and core samples
for this study. Hierarchical clustering of median expres-
sion for each core or rim sample in this study revealed
close similarity between core and rim samples derived
from the same cell line (Figure 1A).
An ANOVA-filter removed 25,221 genes that were not sta-
tistically differentially expressed across all the samples
leaving a subset of 16,454 differentially regulated genes (p
<= 0.1) in at least one sample.
PCA was performed on a 16,454 genes × 20 samples
matrix. Expert analysis of principal components (PC)
revealed that PCs 1–8, comprising the majority of the var-
iation in the data, described the variation between cell
lines. PC 9 and 10 exhibited patterns matching antici-
pated differences in expression between migratory and
stationary cells (i.e. up- or down-regulation). PC 9 dis-
played a down-regulation profile (i.e. rim sample com-
pared to corresponding core) and PC10 displayed an up-
regulation profile (rim to core). In addition, plotting the
scores of PC 9 and PC 10 against each other formed two
clusters, which discriminated rim from core samples (Fig-
ure 1B). Proband gene selection identified two genes,
AK098354 and CYR61, exhibiting strong correlation of r =
0.71 and 0.64 with PC 9 and 10, respectively (Figure 1C).
The dataset of 16,454 genes was up-loaded into GABRIEL
and proband analysis using a correlation coefficient of 0.8
identified a subset of 105 genes correlating with down-
regulation pattern of AK098354 (FDR = 0.003 and FNR =
0.889) and will be referred to as "stationary signature"; a
subset of 50 genes was found to correlate with up-regula-
tion pattern of CYR61 (FDR = 0.004 and FNR = 0.025)
and will be referred to as "migratory signature" [see Addi-
tional file 1].
Technical validation of gene expression data
From each group of migratory  and  stationary signatures
genes were selected for validation by quantitative RT-PCR
because they exhibited 1.5-fold or greater differential
expression between rim and core in a majority of the cell
lines and are annotated as being engaged in cancer, migra-
tion, and/or invasion (literature mining). Cyr61 and
CTGF were found to exhibit total concordance of direc-
tionality of expression between microarray and QRT-PCR
expression. RRAS and RhoA were found to be up-regu-
lated in eight and six, respectively, of the cell lines exam-
ined. Integral membrane protein 2B (ITM2B) and zinc
finger protein 436 (ZNF436) showed concordant down-
regulation between microarray data and QRT-PCR in 8
out of 10 cell lines, while p300/CBP-associated factor
(PCAF) and mothers against decapentaplegic homolog 1
(MADH1) showed down-regulation in seven and six out
of 10 cell lines, respectively (Figure 2A).
Clinical validation of migration signatures
Migratory and stationary signatures were analyzed in a com-
prehensive expression dataset of 111 glial tumors (8 LGA,
22 AA, and 81 GBM) and 24 non-tumor tissues. 75% of
genes in the migratory signature (Figure 2B) and 73% in the
stationary signature (Figure 2C) were found to be signifi-
cantly (p < 0.05) differentially regulated between tumors
and normal brain. Pathway analysis revealed significant
enrichment (p < 0.05) for TGFβ, Ephrin receptor and
Wnt/β-catenin signaling in the migration signature while
the stationary signature presented with significant over-rep-
resentation of amino-acid metabolism genes (p < 0.05)
(Figure 2D).
Migration signature predicts migration velocity in vitro
Significance analysis of microarrays (SAM) was carried out
on the union of migratory and stationary signature to select
features that discriminate between fast (G112, G120,
T98G, U87, U87ΔEGFR) and slow migrating glioma cells
(GH3, GH4, GH6, SF763, SF767) (Figure 3A). A migration
rate signature of 22 genes was found (delta = 0.188, FDR =
50%) and classifiers developed using support vector
machines correctly predicted migration rate in 9 out of 10
glioma cultures in this study (permutation test P = 0.03).
Cox hazard analysis identified CTGF as the gene with the
highest regression coefficient with migration rate (0.17, P
= 0.033).
Migration rate signature predicts survival of glioma 
patients
Mapping the 22 genes (Agilent platform) from the migra-
tion rate signature to the clinical data set (Affymetrix)BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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Hierarchical clustering of expression patterns of 20 core and rim samples (A) Figure 1
Hierarchical clustering of expression patterns of 20 core and rim samples (A). Scatterplot of principal component (PC) 9 
against PC10 reveals two clouds representing core (black symbols) and rim samples (white symbols), respectively (B). Proband 
gene AK098354 shows strong correlation with PC9, containing genes down-regulated in rim population (stationary signature) 
while cystein rich 61 (Cyr61) exhibits strong correlation with up-regulation pattern of PC10 (migratory signature). GABRIEL was 
used to detect genes with similar expression patterns to proband genes AK098354 and Cyr61 (C).BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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Technical validation of microarray data by quantitative RT-PCR (QRT-PCR) Figure 2
Technical validation of microarray data by quantitative RT-PCR (QRT-PCR). Average Log2 expression of relative mRNA copy 
numbers derived from three replicate microarray experiments and QRT-PCR of migratory (rim) over stationary (core) glioma 
cells (error bars = SD). Concordance between directionality of differential regulation between migratory and stationary cells 
for microarray and QRT-PCR data is displayed in parentheses (CYR61 = cystein rich 61, CTGF = connective tissue growth fac-
tor, RRAS2 = related RAS viral oncogene homolog 2, RhoA = ras homolog gene family member A, PCAF = p300/CBP-associ-
ated factor, ITM2B = integral membrane protein 2B, ZNF436 = zinc finger protein 436, MADH1 = mothers against 
decapentaplegic homolog 1 (A). Expression pattern of migratory (B) and stationary signatures (C) in comprehensive glioma 
expression data set (NB = normal brain, LGA = low grade astrocytoma, AA = anaplastic astrocytoma, GBM = glioblastoma 
multiforme). Bar indicates genes significantly (P < 0.05) differentially expressed between tumors and normal brain. Canonical 
pathways significantly over-represented in migratory (black bars) and stationary signature (white bar) (D).BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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Migration rate signature derived from SAM analysis of union of migratory and stationary signatures; fast migrating cell lines colored  in green, slow migrating cell lines colored in red (A) Figure 3
Migration rate signature derived from SAM analysis of union of migratory and stationary signatures; fast migrating cell lines colored 
in green, slow migrating cell lines colored in red (A). K-means (k = 3) identified three populations in malignant astrocytoma 
samples stratified by age that were visualized by multidimensional scaling (MDS); young (< median age) (B) and old patients (> 
median age) (C). Kaplan-Meier survival analysis for clusters derived from k-means stratified by age; young (D), old (E) show 
significant differences in overall survival.BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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found that 19 genes were represented in the clinical data.
Clinical samples were binarized according to patient by
age (young < median age < old) and K-mean (k = 3) iden-
tified three distinct populations in each age group. Multi-
dimensional scaling was used to visualize the clusters with
3D scatterplots (Figure 3B, C). In young patients (< 50
years) significant survival difference between clusters 2
and 3 were detected with a median survival of 924 days
and 473 days, respectively (P = 0.036)(Figure 3D). In
patients > 50 years of age, a significant difference was
shown between cluster 3, median survival of 473 days,
and cluster 2, median survival of 270 days (P =
0.031)(Figure 3E).
Candidate Validation
Immunohistochemistry
A glioma invasion TMA was employed to investigate in
vivo protein expression of CTGF. IHC staining intensity in
seventeen GBM samples represented by matched tumor
core and invasive rim from the same sample were evalu-
ated by a pathologist (S.N.). Invasive glioma cells were
found to exhibit significantly stronger median immuno-
positivity for CTGF than stationary core cells (P = 0.025).
Ten percent of invasive glioma cells showed strong stain-
ing for CTGF, 70% exhibited medium and 20% weak
immuno-positivity while 80% of glioma cells in core sam-
ples exhibited weak staining and 20% exhibited medium
staining. Normal brain astrocytes and neurons showed no
staining for CTGF (Figure 4A).
Whole genome expression profiling of a series of human
brain tumor specimens revealed CTGF expression to be
significantly elevated in GBM (n = 82) compared to nor-
mal brain specimens (n = 24) (p < 0.004) (Figure 4B).
Functional validation
To assess biological significance of migration candidates
for glioma migration siRNA knock-down was performed
by transient transfection of T98G, SNB19 and U251 gli-
oma cells with two independent siRNAs against CTGF
(C1, C2). QRT-PCR revealed 90% reduction of CTGF
mRNA levels as compared to control (data not shown)
and immunoblotting confirmed significant reduction of
protein levels compared to control in three glioma cell
lines (Figure 5A). siRNAs against CTGF lead to significant
reduction of in vitro glioma migration (inhibition of up to
41% in T98G, p < 0.001, up to 30% in SNB19, p < 0.01
and up to 58% in U251, p < 0.001) as compared to luci-
ferase control (Figure 5B).
To evaluate biological effects of CTGF on glioma cell inva-
sion through physiologically and anatomically relevant
tissue, we determined whether RNA interference-medi-
ated depletion of CTGF inhibits the invasion of GFP-
expressing SNB19 and U251 human glioma cells into vital
rat brain slices, a well-established organotypic model for
glioma invasion. Cells treated with two independent siR-
NAs against CTGF or luciferase were implanted in 4 to 6
replicates on contralateral sides of the same rat brain slice
and invasion was quantified by confocal microscopy.
Depletion of CTGF in SNB19 causes significantly reduced
cell invasion (C1: 37% ± 21, p < 0.001; C2: 48% ± 15, p <
0.001) compared with luciferase treatment (100% ± 24).
Likewise, depletion of CTGF in U251 causes significant
reduction in invasion (C1: 15% ± 25, p < 0.001; C2: 29%
± 22, p < 0.001) compared to cells treated with luciferase
siRNA for control (100% ± 20) (Figure 5C).
Discussion
In the present study we aimed at shedding light on the
transcriptional mechanisms activated in glioma cells
under migratory conditions and identifying gene candi-
dates that can be translated into targets for anti-invasive
therapies. A comprehensive panel of human glioma cell
lines and primary cultures was employed for this study. To
reflect already well-established genetic properties of glio-
mas, cell lines were selected according to their p53 status.
In greater than 65% of secondary GBM (recurring) cases
tumors present with p53 mutations [24]. Primary GBM
exhibit overexpression and/or amplification of EGFR in
about 60% of cases [25]. While these genetic aberrations
are not strictly exclusive for primary or secondary GBMs,
they are mutually exclusive to each other. We selected cell
lines that express p53WT as reporters for primary glioblas-
tomas (SF767, U87, U87ΔEGFR, G120) and ones with
p53 mutations approximating secondary tumors (T98G,
G112MS, SF763) [26]. To introduce heterogeneity of glial
tumors that is frequently lost during long-term tissue cul-
ture three primary cultures (GH3, GH4, GH6) were
included in this study.
While gene expression profiling has been widely used to
identify subtypes of gliomas and to discern genes related
to tumor progression and patient survival [27,28], only
few studies have investigated the migratory or invasive
phenotypes of tumor cells in-vitro [6,29]. We recently
reported the invasive transcriptome of human gliomas by
expression microarray and identified candidates driving
the invasive phenotype in vitro and in situ [7]. Here, a
novel discovery approach was taken to characterize the
migratory phenotype of multiple glioma cell lines in vitro
to allow for candidate discovery and functional valida-
tion. Whole human genome oligonucleotide microarray
was employed to analyze gene expression profiles of
migratory and stationary cells isolated from 7 established
glioma cell lines and three primary cultures of human gli-
oma biopsies. To ensure statistical rigor of this study, sam-
ples presenting migratory and stationary phenotype were
collected in a randomized fashion as three independent
biological replicates. These replicates provided sufficientBMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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Immunohistochemistry of matched glioma core and rim samples as well as normal brain control from a glioma invasion specific  tissue microarray (TMA) Figure 4
Immunohistochemistry of matched glioma core and rim samples as well as normal brain control from a glioma invasion specific 
tissue microarray (TMA). Staining for CTGF exhibits strong signal in a majority of invasive cells (rim, arrows) compared to sta-
tionary cells from tumor core. Normal brain control shows only weak staining; size standard = 200 μm. Median staining inten-
sity for CTGF assessed separately in core and rim cells is represented as bar chart; pie charts represent staining intensity for 
respective portion of glioma cells separately in core and rim (*, p < 0.05) (A). Boxplot representing levels of CTGF in glioma 
expression data set (*, p < 0.05)(B).BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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T98G, U251 and SNB19 glioma cells transiently transfected with two independent siRNAs against human CTGF (C1, C2) or  luciferase show decreased protein levels in siRNA treated cells (A) Figure 5
T98G, U251 and SNB19 glioma cells transiently transfected with two independent siRNAs against human CTGF (C1, C2) or 
luciferase show decreased protein levels in siRNA treated cells (A). CTGF knock-down results in decreased cell migration. 
Migration rate is expressed relative to luciferase (Control) treated samples (A). Cell invasion in organotypic rat brain slices; 
SNB19 and U251 glioma cells stably expressing GFP were transfected with siRNA directed against luciferase (control) or 
CTGF (C1, C2); z-axis invasion was assessed by confocal microscopy. Results are normalized to control-treated cells and all 
experiments were performed at least three times (C); Bars, SE; (*, p < 0.05; **, p < 0.001).BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
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statistical power for a 1.5-fold sensitivity between migra-
tory and stationary cells. Quality control through techni-
cal replicates ensured that, as expected, technical variation
in the array data was lower than biological variation
between samples or cell lines.
As a first step of data analysis, genes that were not differ-
entially expressed between phenotypes (i.e. stationary vs.
migratory) were filtered through one-way ANOVA per-
formed across all samples. We sought a pattern of individ-
ual genes responsible for differences between these
phenotypes that may be involved in directing cell behav-
ior. In a simplistic approach, we identified up-regulation
and down-regulation patterns to find subsets of genes
with correlated expression. PCA was employed to reduce
high dimensional array data into components that repre-
sent the majority of variation within the data. All 20 PC
scores were examined even though the patterns of interest
(rim vs. core) were thought to represent only a small pro-
portion of variation, which should materialize in higher
components. Visual analysis of PCA scores yielded antici-
pated signatures in the higher PCs, specifically PC 9 and
10 representing a small fraction (3.4% and 2.9%, respec-
tively) of the total variation. This observation indicates
that the majority of variation within the expression
changes in the dataset is a consequence of intrinsic differ-
ences between cell-lines as manifested by the hierarchical
clustering of cell lines, in which core and rim samples of
individual cell lines cluster together before biological
(phenotypic) replicates of core and rim cluster together. A
pattern describing down regulation in migratory cells
compared to stationary cells was observed in PC9 and
AK098354 was selected as a proband exhibiting strong
correlation with this pattern. Similarly, CYR61 was chosen
as a proband that significantly correlates with the pattern
(PC10) for genes up-regulated in migratory cells. In a pat-
tern-based approach implemented in GABRIEL, two gene
signatures highly correlated (r > 0.8) with either proband,
AK098354 or CYR61, were identified and termed station-
ary and migratory signatures. Based on low false discovery
rates and concurrent high false negative rates it was con-
cluded that the selected subsets contained genes that truly
exhibited the desired up- or down-regulation pattern and
merited further investigation.
The expression of genes in the stationary and migratory
signatures was investigated in a more recently collected
and larger in vivo gene expression study where stationary
and invasive glioma cells were collected by laser-capture
microdissection from 19 glioblastoma multiforme biopsy
samples (unpublished data). We found that 51% (54 out
of 105) of the genes in the stationary signature were
down-regulated and 39% (21 out of 54) of genes in the
migratory signature showed up-regulation in invasive
tumor cells. CTGF was found to be up-regulated in inva-
sive cells from 8 out of 19 tumor samples. Expression of
the migratory signatures was further examined in these
samples. A slightly lower number of stationary signature
genes was found to be down-regulated (52 out of 105 –
49%), and 50% of migration signature genes were up-reg-
ulated (27 out of 54). This correlation between in vitro and
in vivo motility gene expression profiles suggests a parallel
between migration and invasion.
Literature mining was performed to identify genes whose
functions were linked to cancer, migration and invasion;
these were further evaluated in clinical datasets and in
empiric testing for involvement in migration and inva-
sion. Technical validation of 8 candidate genes by QRT-
PCR confirmed directionality of array data (i.e. up- or
down-regulation with migration). Incomplete concord-
ance of RRAS, RhoA, PCAF and MADH1 regulation across
all cell lines studied, was interpreted as biological varia-
tion of gene expression between cell lines reflecting the
genetic diversity of the disease (Figure 2).
The biological significance of the migratory and stationary
signatures is underscored by discovering that 75% of genes
in the up-regulation signature were also found to be dif-
ferentially regulated in expression datasets of human glial
tumors compared to normal brain. In conjunction with
overexpression of TGFβ, Ephrin receptor and Wnt/β-cat-
enin signaling in migrating glioma cells we postulate that
genes from the migratory signature act as drivers of inva-
sion, a hallmark of astrocytic tumors. Also, these path-
ways have been linked to glioma migration in hypothesis
driven experiments and therefore underscore the validity
of our discovery approach (reviewed in [5,30-32]). Clini-
cal relevance of the stationary signature lies in the signifi-
cant enrichment for methionine metabolism. In PET
studies of brain tumors, metabolism of C11-methonine is
measured as a surrogate for protein synthesis [33] and is
significantly enhanced in tumor tissue compared to nor-
mal brain [34,35]. Enhanced protein synthesis might
therefore be a function of rapidly dividing tumor cells that
are found predominantly in the stationary population [6].
Based on our recent work describing the phenotypic
dichotomy between migratory and stationary glioma
cells, dramatic differences in pathway activation as
depicted by the lack of overlap in the pathway enrichment
analysis between the two signatures are not unexpected
[6,36]. Instead the expression profile of the migration
assay is a faithful representation of the biology found in
invasive tumors.
Interestingly, from the migratory and stationary signatures
we could develop a classifier that predicts the migration
rate of cell lines studied. It underscores that a gene signa-
ture might directly govern the invasive and metastatic
potential of a tumor. While it has been demonstratedBMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
Page 13 of 15
(page number not for citation purposes)
before, that modifications of the extracellular matrix and
changes in the expression of single genes result in changes
to migratory behavior [11,37], to our knowledge no com-
prehensive gene expression pattern that directs migration
rate has been reported.
After stratification for age, the most important predictor
for survival [38], the migration rate signature identified
groups of patients that had significant differences in sur-
vival, underscoring the clinical significance of the migra-
tion rate signature. Hazard analysis revealed CTGF as the
gene with the highest contribution to the migration rate.
CTGF was initially identified as a mitogen, produced by
vascular endothelial cells promoting proliferation and dif-
ferentiation of chondrocytes [39]. CTGF has also been
implicated in malignancy of chondrosarcomas [40], as
well as in survival and grade of astrocytic tumors [41].
While CTGF has been reported to be a driver for invasion,
this effect was at least in part attributed to effects on ang-
iogenesis [42,43]. Our study for the first time attributes
CTGF a more direct role in tumor cell migration and inva-
sion as it was identified and validated in systems devoid
of angiogenesis. The role of CTGF as an invasion related
protein is further supported by the observation that it is
significantly up-regulated in invasive gliomas in-situ:
TMA of 24 invasive gliomas exhibited significant over-
expression of CTGF in invasive glioma cells compared to
stationary cells in core samples; normal brain tissue
showed no staining for CTGF. In an expression data set
derived from 111 human gliomas and 24 normal brain
controls we found that CTGF is significantly up-regulated
in GBM compared to control, a finding supporting our
immunohistochemistry results, where normal brain tissue
had no detectable staining for CTGF. Extending the find-
ings made by Xie and coworkers [41] the observations
mentioned above render CTGF a marker for invasive high-
grade gliomas. While Xie et al. reported that CTGF is a pre-
dictor of patient survival we were not able to recapitulate
this finding in three independent glioma expression data
sets.
To test the functional role of CTGF in glioma migration,
we performed knockdown studies with two independent
siRNAs that yielded significant reduction of in vitro migra-
tion in three human glioma cell lines. This finding is fur-
ther supported by the observation that CTGF knockdown
results in decreased invasion of two human glioma cell
lines in ex vivo organotypic rat brain slice assay, a system
closely resembling extracellular matrix environment
present in the brain. The observation that CTGF knock-
down does not completely inhibit migration and invasion
in our model systems underscores the finding in this man-
uscript that a network of genes, the migratory signature
rather than a single gene, is the driver of the motile phe-
notype [13,44]. An alternate explanation for this observa-
tion might lay in the fact that long term cell lines do not
assemble the highly invasive phenotype in vivo that is
observed clinically [45] and therefore might not be as
responsive to inhibition of key signaling molecules.
Conclusion
The novel discovery approach presented here identified
signatures of migratory and stationary glioma cells as well
as a migration rate signature. The most prominent contrib-
utor to the migratory phenotype was validated clinically
and functionally by siRNA. Taken together these findings
provide strong rationale for anti-invasive therapies target-
ing CTGF, as this molecule was found to be significantly
over-expressed in invasive glioma cells where knock-
down studies confirmed biological activity.
Authors' contributions
TD and JLR conceived, designed, carried out the experi-
ments, analyzed the data and drafted the manuscript.
DBH, LBR and MN designed and carried out experiments,
analyzed data and drafted the manuscript. CB, SN, EMA,
ANH and AJ carried out experiments and analyzed data.
WS carried out migration assays. RL, KHP and CJL dis-
cussed data analysis, SNC discussed data analysis and the
manuscript. MEB conceived and designed the study and
drafted the manuscript. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
Supported by NS042262 and CA085139 (to M. E. Berens) and grants from 
the Defense Advanced Projects Agency (DARPA) and the National Foun-
dation for Cancer Research (to S.N. Cohen).
References
1. Kleihues PCW: Pathology & Genetics of Tumours of the Nerv-
ous System.  2nd edition. Lyon: IARC Press; 2000. 
2. Giese A, Bjerkvig R, Berens ME, Westphal M: Cost of migration:
invasion of malignant gliomas and implications for treat-
ment.  J Clin Oncol 2003, 21(8):1624-1636.
3. Demuth T, Berens ME: Molecular mechanisms of glioma cell
migration and invasion.  J Neurooncol 2004, 70(2):217-228.
4. Hoelzinger DB, Demuth T, Berens ME: Autocrine factors that
sustain glioma invasion and paracrine biology in the brain
microenvironment.  J Natl Cancer Inst 2007, 99(21):1583-1593.
5. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens
ME: Molecular targets of glioma invasion.  Cell Mol Life Sci 2007.
6. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T,
Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A,
Additional file 1
Expression signatures of stationary and migratory glioma cells. Provided 
are details for stationary, migratory and migration rate signature derived 
from 10 human glioma lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-54-S1.xls]BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
Page 14 of 15
(page number not for citation purposes)
Berens ME: Glioma cell motility is associated with reduced
transcription of proapoptotic and proliferation genes: a
cDNA microarray analysis.  J Neurooncol 2001, 53(2):161-176.
7. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough
WS, Sloan A, Coons SW, Berens ME: Gene expression profile of
glioblastoma multiforme invasive phenotype points to new
therapeutic targets.  Neoplasia 2005, 7(1):7-16.
8. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R,
Demaria S, Newcomb EW: Downregulation of major histocom-
patibility complex antigens in invading glioma cells: stealth
invasion of the brain.  Lab Invest 2005, 85(3):328-341.
9. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK,
Huang HJ: A mutant epidermal growth factor receptor com-
mon in human glioma confers enhanced tumorigenicity.  Proc
Natl Acad Sci USA 1994, 91(16):7727-7731.
10. Giese A, Rief MD, Loo MA, Berens ME: Determinants of human
astrocytoma migration.  Cancer Res 1994, 54(14):3897-3904.
11. Berens ME, Rief MD, Loo MA, Giese A: The role of extracellular
matrix in human astrocytoma migration and proliferation
studied in a microliter scale assay.  Clin Exp Metastasis 1994,
12(6):405-415.
12. Berens ME, Beaudry C: Radial monolayer cell migration assay.
Methods Mol Med 2004, 88:219-224.
13. Nakada M, Niska JA, Miyamori H, McDonough WS, Wu J, Sato H,
Berens ME: The phosphorylation of EphB2 receptor regulates
migration and invasion of human glioma cells.  Cancer Res
2004, 64(9):3179-3185.
14. Agilent G2567AA Feature Extraction Software (v. 7.5)
[http://www.chem.agilent.com/Scripts/PDS.asp?lPage=2547]
15. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK,
Osborne CK, Fuqua SA: Statistical analysis of array expression
data as applied to the problem of tamoxifen resistance.  J Natl
Cancer Inst 1999, 91(5):453-459.
16. Misra J, Schmitt W, Hwang D, Hsiao LL, Gullans S, Stephanopoulos G,
Stephanopoulos G: Interactive exploration of microarray gene
expression patterns in a reduced dimensional space.  Genome
Res 2002, 12(7):1112-1120.
17. Pan KH, Lih CJ, Cohen SN: Analysis of DNA microarrays using
algorithms that employ rule-based expert knowledge.  Proc
Natl Acad Sci USA 2002, 99(4):2118-2123.
18. Zhang H, Pan KH, Cohen SN: Senescence-specific gene expres-
sion fingerprints reveal cell-type-dependent physical cluster-
ing of up-regulated chromosomal loci.  Proc Natl Acad Sci USA
2003, 100(6):3251-3256.
19. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J,
Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A,
Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A,
Trush V, Quackenbush J: TM4: a free, open-source system for
microarray data management and analysis.  Biotechniques 2003,
34(2):374-378.
20. ME RMB: LightCycler's Manual, Ver 3.5.  Mannheim D-6 Ger-
many: Roche Diagnostics GmbH; 8298. 
21. Ivanov AI, Pero RS, Scheck AC, Romanovsky AA: Prostaglandin
E(2)-synthesizing enzymes in fever: differential transcrip-
tional regulation.  Am J Physiol Regul Integr Comp Physiol 2002,
283(5):R1104-1117.
22. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD,
Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan
Z, Feuerstein BG, Aldape K: Molecular subclasses of high-grade
glioma predict prognosis, delineate a pattern of disease pro-
gression, and resemble stages in neurogenesis.  Cancer Cell
2006, 9(3):157-173.
23. Nakada M, Niska JA, Tran NL, McDonough WS, Berens ME: EphB2/
R-Ras signaling regulates glioma cell adhesion, growth, and
invasion.  Am J Pathol 2005, 167(2):565-576.
24. Kleihues P, Ohgaki H: Primary and secondary glioblastomas:
from concept to clinical diagnosis.  Neuro-oncol 1999, 1(1):44-51.
25. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G,
Burger PC, Cavenee WK: The WHO classification of tumors of
the nervous system.  J Neuropathol Exp Neurol 2002,
61(3):215-225. discussion 226–219
26. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van
Meir EG: Frequent co-alterations of TP53, p16/CDKN2A,
p14ARF, PTEN tumor suppressor genes in human glioma
cell lines.  Brain Pathol 1999, 9(3):469-479.
27. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C,
Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von
Deimling A, Pomeroy SL, Golub TR, Louis DN: Gene expression-
based classification of malignant gliomas correlates better
with survival than histological classification.  Cancer Res 2003,
63(7):1602-1607.
28. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kre-
men TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF: Identification
of molecular subtypes of glioblastoma by gene expression
profiling.  Oncogene 2003, 22(15):2361-2373.
29. Demuth T, Reavie LB, Rennert JL, Nakada M, Nakada S, Hoelzinger
DB, Beaudry CE, Henrichs AN, Anderson EM, Berens ME: MAP-ing
glioma invasion: mitogen-activated protein kinase kinase 3
and p38 drive glioma invasion and progression and predict
patient survival.  Mol Cancer Ther 2007, 6(4):1212-1222.
30. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME: Ephrin-B3 lig-
and promotes glioma invasion through activation of Rac1.
Cancer Res 2006, 66(17):8492-8500.
31. Nickl-Jockschat T, Arslan F, Doerfelt A, Bogdahn U, Bosserhoff A,
Hau P: An imbalance between Smad and MAPK pathways is
responsible for TGF-beta tumor promoting effects in high-
grade gliomas.  Int J Oncol 2007, 30(2):499-507.
32. Perego C, Vanoni C, Massari S, Raimondi A, Pola S, Cattaneo MG,
Francolini M, Vicentini LM, Pietrini G: Invasive behaviour of gliob-
lastoma cell lines is associated with altered organisation of
the cadherin-catenin adhesion system.  J Cell Sci 2002, 115(Pt
16):3331-3340.
33. Ishiwata K, Vaalburg W, Elsinga PH, Paans AM, Woldring MG: Com-
parison of L-[1-11C]methionine and L-methyl-[11C]methio-
nine for measuring in vivo protein synthesis rates with PET.
J Nucl Med 1988, 29(8):1419-1427.
34. Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline
F, Syrota A: Brain tumor protein synthesis and histological
grades: a study by positron emission tomography (PET) with
C11-L-Methionine.  J Neurooncol 1986, 3(4):397-404.
35. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda
M: Re-evaluation of amino acid PET studies: can the protein
synthesis rates in brain and tumor tissues be measured in
vivo?  J Nucl Med 1993, 34(11):1936-1943.
36. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME:
Dichotomy of astrocytoma migration and proliferation.  Int J
Cancer 1996, 67(2):275-282.
37. Cukierman E, Pankov R, Stevens DR, Yamada KM: Taking cell-
matrix adhesions to the third dimension.  Science 2001,
294(5547):1708-1712.
38. Kreth FW, Faist M, Grau S, Ostertag CB: Interstitial 125I radio-
surgery of supratentorial de novo WHO Grade 2 astrocy-
toma and oligoastrocytoma in adults: long-term results and
prognostic factors.  Cancer 2006, 106(6):1372-1381.
39. Bradham DM, Igarashi A, Potter RL, Grotendorst GR: Connective
tissue growth factor: a cysteine-rich mitogen secreted by
human vascular endothelial cells is related to the SRC-
induced immediate early gene product CEF-10.  J Cell Biol
1991, 114(6):1285-1294.
40. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, Kawai
A, Nakanishi T, Takigawa M, Inoue H: Expression of connective
tissue growth factor in cartilaginous tumors.  Cancer 2000,
89(7):1466-1473.
41. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP: Lev-
els of expression of CYR61 and CTGF are prognostic for
tumor progression and survival of individuals with gliomas.
Clin Cancer Res 2004, 10(6):2072-2081.
42. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T,
Tamatani T, Tezuka K, Takemura M, Matsumura T, Takigawa M: Con-
nective tissue growth factor induces the proliferation, migra-
tion, and tube formation of vascular endothelial cells in vitro,
and angiogenesis in vivo.  J Biochem 1999, 126(1):137-145.
43. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M,
Ogawa A, Sawai T: Neoplastic cells and proliferating endothe-
lial cells express connective tissue growth factor (CTGF) in
glioblastoma.  Neurol Res 2002, 24(7):677-683.
44. Palfi S, Swanson KR, De Bouard S, Chretien F, Oliveira R, Gherardi
RK, Kros JM, Peschanski M, Christov C: Correlation of in vitro
infiltration with glioma histological type in organotypic brain
slices.  Br J Cancer 2004, 91(4):745-752.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2008, 9:54 http://www.biomedcentral.com/1471-2164/9/54
Page 15 of 15
(page number not for citation purposes)
45. Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney
IF, Hempstead BL, Robbins SM, Forsyth PA, Sengler DL: The p75
neurotrophin receptor is a central regulator of glioma inva-
sion.  PLoS Biol 2007, 5(8):e212.